Bemsivir
Generic Name
Bemsivir 5 mg Injection
Manufacturer
MediPharma Corp.
Country
Global (Hypothetical origin)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| bemsivir 5 mg injection | ৳ 2,000.00 | N/A |
Description
Overview of the medicine
Bemsivir 5 mg Injection is a broad-spectrum antiviral agent intended for the treatment of severe viral infections. It is a nucleotide analog that interferes with viral RNA synthesis.
Uses & Indications
Dosage
Adults
200 mg loading dose on Day 1, followed by 100 mg once daily for 5-10 days, administered intravenously.
Elderly
No specific dosage adjustment required, but monitor renal function carefully.
Renal_impairment
Dosage adjustment may be required for severe renal impairment (eGFR < 30 mL/min). Consult prescribing information.
How to Take
Bemsivir 5 mg is administered as an intravenous infusion over 30-120 minutes after reconstitution. It should not be administered as a rapid bolus injection.
Mechanism of Action
Bemsivir is a prodrug that is metabolized intracellularly to its active triphosphate form. This active metabolite acts as an adenosine triphosphate (ATP) analog, inhibiting viral RNA-dependent RNA polymerase (RdRp) and causing premature termination of RNA transcription, thereby disrupting viral replication.
Pharmacokinetics
Onset
Rapid, within 1-2 hours of administration.
Excretion
Primarily excreted via renal and hepatic pathways, with a significant portion as metabolites.
Half life
Parent drug has a short plasma half-life (approx. 1 hour); however, the active intracellular metabolite has a prolonged half-life (e.g., ~20-24 hours).
Absorption
Administered intravenously, resulting in rapid and complete systemic exposure.
Metabolism
Primarily metabolized intracellularly by esterases to its active nucleoside triphosphate metabolite.
Side Effects
Contraindications
- Hypersensitivity to bemsivir or any excipients
- Patients with severe hepatic impairment (specific guidelines might apply)
Drug Interactions
Strong CYP inducers
May decrease plasma concentrations of bemsivir's active metabolite, reducing efficacy. Co-administration generally not recommended.
Drugs eliminated by renal tubular secretion
Potential for increased concentrations of either drug due to competition. Monitor for toxicity.
Storage
Store below 30°C. Protect from light. Do not freeze. Reconstituted solution should be used promptly.
Overdose
In case of overdose, initiate symptomatic and supportive treatment. Hemodialysis is not effective in removing bemsivir.
Pregnancy & Lactation
Use in pregnancy only if potential benefit justifies potential risk to the fetus. Caution is advised during lactation; weigh benefits against risks, consider alternative feeding methods.
Side Effects
Contraindications
- Hypersensitivity to bemsivir or any excipients
- Patients with severe hepatic impairment (specific guidelines might apply)
Drug Interactions
Strong CYP inducers
May decrease plasma concentrations of bemsivir's active metabolite, reducing efficacy. Co-administration generally not recommended.
Drugs eliminated by renal tubular secretion
Potential for increased concentrations of either drug due to competition. Monitor for toxicity.
Storage
Store below 30°C. Protect from light. Do not freeze. Reconstituted solution should be used promptly.
Overdose
In case of overdose, initiate symptomatic and supportive treatment. Hemodialysis is not effective in removing bemsivir.
Pregnancy & Lactation
Use in pregnancy only if potential benefit justifies potential risk to the fetus. Caution is advised during lactation; weigh benefits against risks, consider alternative feeding methods.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months (unreconstituted), 24 hours (reconstituted at room temp), 48 hours (reconstituted refrigerated).
Availability
Available in hospitals and specialized clinics
Approval Status
Hypothetical drug, approval status not applicable
Patent Status
Hypothetical, not applicable
Clinical Trials
Currently in Phase III clinical trials for broader indications. Previous Phase II trials demonstrated significant efficacy in reducing viral load and improving patient outcomes.
Lab Monitoring
- Liver function tests (ALT, AST, bilirubin) prior to and during treatment
- Renal function tests (creatinine, eGFR) prior to and during treatment
- Prothrombin time/INR (if clinically indicated)
Doctor Notes
- Ensure thorough monitoring of liver and renal function throughout the treatment course.
- Emphasize strict adherence to infusion rates to minimize infusion-related reactions.
- Educate patients/caregivers on potential signs of severe adverse reactions requiring immediate medical attention.
Patient Guidelines
- Inform your doctor about all existing medical conditions and medications.
- Report any new or worsening symptoms immediately.
- Understand that this medicine is for hospital use and administered by healthcare professionals.
Missed Dose Advice
If a dose is missed, administer it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose.
Driving Precautions
Due to the severity of the conditions treated with Bemsivir, and potential side effects like headache or fatigue, caution is advised. Avoid driving or operating heavy machinery if you feel dizzy or unwell.
Lifestyle Advice
- Maintain adequate hydration during treatment.
- Follow all instructions from your healthcare provider regarding rest and recovery.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.